Associations - EML4-ALK fusion

EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	crizotinib Resistant: C2 – Inclusion Criteria crizotinib Resistant : C2	crizotinib Resistant: C2 – Inclusion Criteria crizotinib Resistant : C2
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3	Tyrosine kinase inhibitor Resistant: C3 – Early Trials Tyrosine kinase inhibitor Resistant : C3
EML4-ALK fusion	Lung Non-Small Cell Squamous Cancer	EML4-ALK fusion	Lung Non-Small Cell Squamous Cancer	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3	Tyrosine kinase inhibitor Sensitive: C3 – Early Trials Tyrosine kinase inhibitor Sensitive : C3
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3	alectinib Sensitive: C3 – Early Trials alectinib Sensitive : C3
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3	durvalumab Resistant: C3 – Early Trials durvalumab Resistant : C3
EML4-ALK fusion	Ovarian Cancer	EML4-ALK fusion	Ovarian Cancer	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4
EML4-ALK fusion	Breast Cancer	EML4-ALK fusion	Breast Cancer	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
EML4-ALK fusion	Lung Adenocarcinoma	EML4-ALK fusion	Lung Adenocarcinoma	Resistant: C4 – Case Studies Resistant : C4	Resistant: C4 – Case Studies Resistant : C4
EML4-ALK fusion	Lung Adenocarcinoma	EML4-ALK fusion	Lung Adenocarcinoma	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4	crizotinib Sensitive: C4 – Case Studies crizotinib Sensitive : C4
EML4-ALK fusion	Lung Non-Small Cell Squamous Cancer	EML4-ALK fusion	Lung Non-Small Cell Squamous Cancer	brigatinib Sensitive: C4 – Case Studies brigatinib Sensitive : C4	brigatinib Sensitive: C4 – Case Studies brigatinib Sensitive : C4
EML4-ALK fusion	Lung Non-Small Cell Squamous Cancer	EML4-ALK fusion	Lung Non-Small Cell Squamous Cancer	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4
EML4-ALK fusion	Neuroendocrine Tumor	EML4-ALK fusion	Neuroendocrine Tumor	lorlatinib Sensitive: C4 – Case Studies lorlatinib Sensitive : C4	lorlatinib Sensitive: C4 – Case Studies lorlatinib Sensitive : C4
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	atezolizumab Sensitive: C4 – Case Studies atezolizumab Sensitive : C4	atezolizumab Sensitive: C4 – Case Studies atezolizumab Sensitive : C4
EML4-ALK fusion	Lung Adenocarcinoma	EML4-ALK fusion	Lung Adenocarcinoma	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4
EML4-ALK fusion	Neuroendocrine Tumor	EML4-ALK fusion	Neuroendocrine Tumor	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4
EML4-ALK fusion	Lung Adenocarcinoma	EML4-ALK fusion	Lung Adenocarcinoma	ensartinib Sensitive: C4 – Case Studies ensartinib Sensitive : C4	ensartinib Sensitive: C4 – Case Studies ensartinib Sensitive : C4
EML4-ALK fusion	Salivary Gland Cancer	EML4-ALK fusion	Salivary Gland Cancer	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4	alectinib Sensitive: C4 – Case Studies alectinib Sensitive : C4
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	Immunotherapy Sensitive: C4 – Case Studies Immunotherapy Sensitive : C4	Immunotherapy Sensitive: C4 – Case Studies Immunotherapy Sensitive : C4
EML4-ALK fusion	Lung Adenocarcinoma	EML4-ALK fusion	Lung Adenocarcinoma	lorlatinib Sensitive: C4 – Case Studies lorlatinib Sensitive : C4	lorlatinib Sensitive: C4 – Case Studies lorlatinib Sensitive : C4
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	MTI-31 Sensitive: D – Preclinical MTI-31 Sensitive : D	MTI-31 Sensitive: D – Preclinical MTI-31 Sensitive : D
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D	ADX-1612 Sensitive: D – Preclinical ADX-1612 Sensitive : D
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	ceritinib Sensitive: D – Preclinical ceritinib Sensitive : D	ceritinib Sensitive: D – Preclinical ceritinib Sensitive : D
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	ceritinib + U0126 Sensitive: D – Preclinical ceritinib + U0126 Sensitive : D	ceritinib + U0126 Sensitive: D – Preclinical ceritinib + U0126 Sensitive : D
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	lorlatinib Resistant: D – Preclinical lorlatinib Resistant : D	lorlatinib Resistant: D – Preclinical lorlatinib Resistant : D
EML4-ALK fusion	Melanoma	EML4-ALK fusion	Melanoma	crizotinib Sensitive: D – Preclinical crizotinib Sensitive : D	crizotinib Sensitive: D – Preclinical crizotinib Sensitive : D
EML4-ALK fusion	Melanoma	EML4-ALK fusion	Melanoma	ceritinib Sensitive: D – Preclinical ceritinib Sensitive : D	ceritinib Sensitive: D – Preclinical ceritinib Sensitive : D
EML4-ALK fusion	Non Small Cell Lung Cancer	EML4-ALK fusion	Non Small Cell Lung Cancer	gilteritinib Sensitive: D – Preclinical gilteritinib Sensitive : D	gilteritinib Sensitive: D – Preclinical gilteritinib Sensitive : D